文献速递临床免疫临床微生物

Chagas TESA VirClia 检测用于慢性克氏锥虫感染诊断及治疗后随访的评价

Evaluation of Chagas TESA VirClia assay for chronic Trypanosoma cruzi infection diagnosis and post-treatment follow-up.
PubMed 文献 · J Clin Microbiol · 2026-06-12

该回顾性诊断准确性研究用 227 份血清样本评估基于天然排泄分泌抗原的 Chagas TESA VirClia 化学发光免疫 assay,对照两种参考血清学检测。结果显示该 assay 与参考检测一致性 93.8%,灵敏度和特异度分别为 92% 和 100%,且仅在 TESA 检测中观察到治疗患者抗体指数随时间更频繁下降。

要点

  • TESA VirClia 与参考血清学检测一致性 93.8%,灵敏度 92%、特异度 100%。
  • 利什曼抗体阳性样本可见有限交叉反应,病毒感染样本未见交叉反应。
  • 治疗患者中 TESA 检测更常显示抗体指数随时间下降。

核心结论

  • Chagas TESA VirClia 可作为慢性克氏锥虫感染诊断流程中的可靠确认工具。
  • 该 assay 是唯一显示治疗后抗体指数随时间一致下降的检测。

研究设计与样本

  • 回顾性诊断准确性研究,使用 227 份血清样本。
  • 样本来自接受慢性克氏锥虫感染检测的个体及有其他寄生虫或病毒感染个体。
  • 感染状态由两种基于重组抗原和天然抗原的参考血清学 assay 确定。

主要发现

  • TESA 检测与参考检测一致性为 93.8%。
  • 灵敏度为 92%,特异度为 100%。
  • 利什曼抗体阳性样本中观察到有限交叉反应,病毒感染样本中未观察到交叉反应。
  • 治疗患者中 TESA 检测更频繁观察到抗体指数随时间下降。

关键数值与推荐

  • 慢性克氏锥虫感染诊断依赖两种不同抗原和/或原理的血清学检测结果一致。
  • 目前唯一接受的治愈标准是血清学由阳性转为阴性,但抗克氏锥虫 IgG 可在治疗后持续多年。

临床怎么用

  • 可将 Chagas TESA VirClia 纳入慢性克氏锥虫感染的诊断算法作为确认工具。
  • 该 assay 有望用于治疗后血清学随访,监测抗体指数下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diagnosis of chronic Trypanosoma cruzi infection relies on the concordant results of two serological tests based on different antigens and/or principles. Currently, the only accepted cure criterion is the switch from positive to negative serology, but anti-T. cruzi IgG may persist for years, even after treatment. Recently, a novel chemiluminescence immunoassay based on native T. cruzi excreted-secreted antigens (TESA)-Chagas TESA VirClia-was developed. This study assessed the performance of this assay for the detection of anti-T. cruzi antibodies for the diagnosis and post-treatment follow-up of chronic T. cruzi infection. A retrospective diagnostic accuracy study was conducted using 227 serum samples, including samples from individuals tested for chronic T. cruzi infection and from individuals with other parasitic or viral infections. T. cruzi infection status was established using two reference serological assays based on recombinant and native antigens. All samples were analyzed by TESA-based assay and compared with the reference tests. Concordance between the TESA-based assay and the reference tests was 93.8%, with a sensitivity and specificity of 92% and 100%, respectively. Limited cross-reactivity was observed in samples positive for Leishmania spp. antibodies, while no cross-reactivity was observed in viral infections. A decrease in antibody index over time was observed more frequently in treated patients when tested by the TESA-based assay. These findings support the use of the Chagas TESA VirClia assay as a reliable confirmatory tool within the diagnostic algorithm for chronic T. cruzi infection. Moreover, this assay was the only test showing a consistent post-treatment decline in antibody index over time.IMPORTANCEThe diagnosis and monitoring of chronic Trypanosoma cruzi infection remain challenging because no single serological test achieves 100% sensitivity and specificity, and the antibodies may persist for many years even after treatment. This study highlights the value of a novel serological assay based on native antigens excreted by the parasite, which more effectively reflects changes in antibody levels over time. Its high diagnostic accuracy and greater ability to detect declining antibody values in treated patients support its use as a reliable diagnostic tool as well as a promising method for serological follow-up.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Silgado A, Mediavilla A, Martínez-Vallejo P, et al. Evaluation of Chagas TESA VirClia assay for chronic Trypanosoma cruzi infection diagnosis and post-treatment follow-up. J Clin Microbiol. 2026. PMID: 42284051. doi:10.1128/jcm.01739-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。